CHARLES C. (CLIFF) PARRISH, M.D.

2665 North Decatur Road STE #550, Decatur, Georgia 30033 | 404-296-1986

EDUCATION:

Medical School MD University of Tennessee 1982-1986
Undergraduate BS University of Tennessee 1978-1982

EDUCATIONAL AWARDS;

Alpha Omega Alpha – Elected as a Junior Medical Student (1985)
Phi Kappa Phi – Elected in junior year in undergraduate studies
Graduated with Highest Honors in both Medical School and in Undergraduate Studies

MEDICAL TRAINING:

Internship: Internal Medicine Vanderbilt University 1986-1987
Residency: Internal Medicine Vanderbilt University 1987-1989
Fellowship: Gastroenterology University of Kentucky 1989-1991

BOARD CERTIFICATION:

Internal Medicine Board Certified 1989
Gastroenterology Board Certified 1991-2021

WORK EXPERIENCE:

Clinical Research Sub-Principal Investigator 2009 – Present
Atlanta Center for Gastroenterology, P.C.
2665 North Decatur Road, Suite 550, Decatur, GA 30033

Gastroenterologist: 1991 – Present
Atlanta Endoscopy Center for Gastroenterology LLC
2665 North Decatur Road, Suite 545, Decatur, GA 30033

Gastroenterologist: 1991 – Present
Atlanta Center for Gastroenterology, P.C.
2665 North Decatur Road, Suite 550 Decatur, GA 30033

Basic Cardiac Life Support Certified 1986 - Present
Emory Decatur Hospital, Decatur, GA. 30033

CHARLES C. (CLIFF) PARRISH, M.D.

2665 North Decatur Road STE #550, Decatur, Georgia 30033 | 404-296-1986

Clinical Research Studies

Sub-Principal Investigator is currently on several Clinical Trials including Crohn's Disease, Active Ulcerative Colitis, Bowel Prep with the following sponsors: Braintree, Janssen, RedHill, GenTech, Quintiles, Tekeda, Ardelyx, Prometheus Laboratories Inc..and Secure. 2015 – Present

Sub-Principal Investigator Protocol **PMDx039 (Project 039-15-01):** Colonoscopy Clinical Specimen Collection Study. **ProMeddx,** 7/2015– 2016.

Sub-Principal Investigator, Protocol **BI 1311.6:** A Phase II, Multicenter, Randomized, Double-blind, Multiple Dose, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of BI 655066, an IL-23 p19 Antagonist Monoclonal Antibody, in Patients With Moderately to Severely Active Crohn's Disease, Who Are naïve to, or Were Previously Treated With Anti-TNF Therapy. **Boehringer-Ingelheim,** 4/2014 – present.

Sub-Principal Investigator Protocol **PMDx039 (Project 039-14-01):** Colonoscopy Clinical Specimen Collection Study. **ProMeddx,** 9/2014 – 5/2015.

Sub-Principal Investigator Protocol **SP-304203-00:** A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients With Chronic Idiopathic Constipation. **Synergy Pharmaceuticals, Inc.** 2/2014 – 5/2015.

Sub-Principal Investigator, Protocol **RNLC2131:** A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Assess the Efficacy Of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications in Subjects with Early Decompensate Liver Cirrhosis. Sub-Principal Investigator, **Salix Pharmaceuticals, Inc**. 08/2013 – 8/2015.

Sub-Principal Investigator Protocol **PMDx039 (Project 039-13-01):** Colonoscopy Clinical Specimen Collection Study. **ProMeddx,** 4/2013 – 12/2013.

Sub-Principal Investigator, Protocol **M14-002:** A Randomized, Double-Blind Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonovir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribovirin (RBV) in Treatment:-Naive Adults with Genotype 1a Chronic Hepatitis C Virus (HCV) Infection (PEARL-IV). **AbbVie,** 04/2013 – 07/2013.

Sub-Principal Investigator, Protocol **BI 1241.20:** A Phase III, Randomized, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination With Faldaprevir and Ribavirin in Treatment Naive Patients with Chronic Genotype 1 HCV Infection. **Boehringer-Ingelheim,** 02/2013 – 12/2014.

Sub-Principal Investigator, Protocol **VEN307-AF-001:** A Phase 3B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Treatment Group, Multicenter Efficacy and Safety Study of Topical Diltazem Hydrochloride 2% Cream in Subjects With

Anal Fissure. **Ventrus Bio-Sciences**, 01/2013 – 1/2014.

Sub-Principal Investigator**: Protocol A7281010 (Turandot II):** A Multicenter Open-Label Extension Study to Assess Long-Term Safety of PF-00547659 in Subjects With Ulcerative Colitis. **Pfizer, Inc.** 01/2013 – 8/2013.

Sub-Principal Investigator, Protocol **A7281009 (Turandot):** A Double- Blind, Randomized,Placebo-Controlled, Parallel, Dose-Ranging Study to Evaluate the Efficacy And Safety of PF-00547659 in Subjects with Moderate to Severe Ulcerative Colitis. **Pfizer, Inc.** 01/2013 – 8/2013.

Sub-Principal Investigator, Protocol **A-12594:** Study protocol for the Validation Of the Ulcerative Colitis Patient-Reported Outcomes (UC-PRO) Instrument in Patients with Ulcerative Colitis. **United Bio-Source Corporation**, 12/2012 - 11/2013

Sub-Principal Investigator, Protocol **ZA-201:** A Phase II Double-Blind, Randomized, Comparator-Controlled, Study of the Safety and Efficacy of Zoenasa™ Rectal Gel (mesalamine plus N-acetylcysteine) in Subjects with Left-sided Ulcerative Colitis. **Altheus Therapeutics, Inc.,** 09/2012 – 01/2013

Sub-Principal Investigator, Protocol **ML27900:** Non-investigationa1, Prospective, Cohort Study of the Effectiveness, Safety, and Utilization of Two Approved Pegylated Interferon-Based Direct Acting Antiviral Triple Therapies in the Management of Genotype 1 Chronic Hepatitis C in Routine Clinical Practicein the USA. **F. Hoffman-LaRoche Ltd, Genentech**, 09/2012 – 8/2014.

Sub-Principal Investigator, Protocol **PMDx037:** HCV Clinical Specimen Collection Study. **ProMeddx,** 2/2012 – present.

Sub-Principal Investigator, Protocol **A3921139 (Octave):** A Multi-Centre, Open-Label Study of CP-690,550 in Subjects with Moderate to Severe Ulcerative Colitis. **Pfizer Inc.**, 07/2012 - Present.

Sub-Principal Investigator, Protocol **A3921096 (Octave):** A Multi-Centre, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of oral CP-690,550, as a Maintenance Therapy in Subjects with Ulcerative Colitis. **Pfizer, Inc.**, 07/2012 – Present.

Sub-Principal Investigator, Protocol **A3921095 (Octave):** A Multi-centre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of oral CP-690,550 as an Induction Therapy in Subjects with Moderate to Severe Ulcerative Colitis. **Pfizer Inc.**, 07/2012 – Present.

Sub-Principal Investigator, Protocol **C2011-0401:** A randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Budesonide MMX 9mg Extended-release Tablets as Add-on therapy in Patients with Active, Mild or Moderate Ulcerative Colitis not Adequately Controlled on a Background Oral 5-ASA Regimen. **Santarus Inc.,** 03/2012 – 08/2013.

Sub-Principal Investigator, Protocol **PMDx039 (Project 039-12-01):** Colonoscopy Clinical Specimen Collection Study. **ProMeddx,** 2/2012 – 1/2013.

Sub-Principal Investigator, Protocol **1220.48:** A Phase III, open-label study of once Daily BI 201335 240mg for 24 weeks in combination with pegylated interferon-a (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C Infection who failed a prior PegIFN *I* RBV treatment. **Boehringer-Ingelheim**, 10/2011 – 8/2014.

Sub-Principal Investigator, Protocol **1220.47:** A Phase III, randomized, double-blind And placebo-controlled study of once daily BI 201335 120mg for 24 weeks and BI 201335 240mg for 12 weeks in combination with pegylated interferon-a and Ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C infection. **Boehringer-Ingelheim**, 05/2011 - 1/2014

Sub-Principal Investigator, Protocol **B0151005**: A Multicenter Open-Label Extension Study for subjects who participated in the Study BO 151003 (ANDANTE II) **Pfizer Inc**., 11/2011 – 2/2015.

Sub-Principal Investigator, Protocol **B0151003:** A Double-Blind, Randomized, Placebo- Controlled, Dose-Ranging study to Evaluated the Efficacy and Safety of PF-04236921 In subjects with Crohn's Disease who are Anti-TNF Inadequate Responders. (ANDANTE) **Pfizer Inc**., 04/2011 - 03/2015.

Sub-Principal Investigator, Protocol **ASMP3001:** A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects with Diarrhea-Predominant Irritable Bowel Syndrome. **Tioga Pharmaceuticals, Inc.,** 04/2010 – 02/2013.

Sub-Principal Investigator, Protocol **C87075:** A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease. **Secure Registry**, 10/2009 – present.

Sub-Principal Investigator, **COLO CP-01-US** Chemoprevention of Colorectal Adenomas An international, multi center, randomized, parallel group, prospective, double blind, placebo controlled clinical trial evaluating the efficacy and safety of a combination treatment administered over 3 years in patients at risk of experiencing recurrence of colorectal adenomas. **ColoTech AS,** 10/2008 – 03/2011

Sub-Principal Investigator, **E3810-G000-301:** Randomized double-blind parallel study of Rabeprazole Extended Release 50 mg versus Esomeprazole 40 mg for healing and symptomatic relief of moderate to severe erosive gastro-esophageal reflux disease (GERD) **Eisai Medical Research**, 09/2008 – present

Sub-Principal Investigator, Protocol: **E3810-G000-303:** Randomized double-blind parallel study of Rabeprazole Extended Release 50 mg versus Esomeprazole 4mg for healing and symptomatic relief of mild to moderate erosive gastro-esophageal reflux disease (GERD) **Eisai Medical Research**, 09/2008 06/2009

Sub-Principal Investigator, Protocol **E3810-A001-307:** A multicenter randomized Double- Blind study to compare the efficacy, safety and tolerability of Rabeprazole ER 50 mg with placebo in subjects with symptomatic gastro-esophageal reflux disease (GERD). **Eisai Medical Research** 09/2008 – 05/2009.

Sub-Principal Investigator, Protocol **C13007:** A Phase 3, Randomized, Placebo- Controlled, Blinded Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Moderate to Severe Crohn's Disease. **Takeda (formerly Millennium) Pharmaceuticals** 09/2008 – 11/2012.

Sub-Principal Investigator, Protocol **C13008:** A Phase 3, Open-label Study to Determine the Long-Term Safety and Efficacy of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis Crohn's Disease. **Takeda (formerly Millennium) Pharmaceuticals** 09/2008 —present.

Sub-Principal Investigator, Protocol **R97-023:** Intron-A-Retrovirus for treatment of patients with Chronic Hepatitis C, not previously treated with Interferon for **Schering Plough Pharmaceuticals.**

Sub-Principal Investigator, A double-blind study to compare the efficacy and safety of **SB-207366A:** (5mg) with placebo in patients with Irritable Bowel Syndrome for **Smith Kline Beechem, Inc.**

Sub-Principal Investigator, Protocol S3B30020: A 24-week Randomized, open label study of health care resource use, quality of life and productivity with Alosetron 1 mg, twice daily, versus traditional therapy in females with non-constipated Irritable Bowel Syndrome for **Glaxo-Wellcome Inc.**

Sub-Principal Investigator, Protocol **DPM03-01:** Dipentum (olsalazine sodium) In the Management of Ulcerative Colitis in Remission: A Multi-Center, Open Label, Post Marketing Clinical Experience Study.

Additional Training:

Protecting Human Research Participants Training (NIH Version), 2/2015
GCP Training for Investigational Staff (Pfizer version 1.2), 03/2011
CITI Course: Basic, Human Subjects Protection Biomedical Focus, 7/2009